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Pharmacokinetics of Colistin Methanesulfonate and Colistin in a Critically Ill
Patient Receiving Continuous Venovenous Hemodiafiltration
Intravenous colistin methanesulfonate (CMS) is increasingly
the last line of defense for multidrug-resistant gram-negative
bacteria and is now being used as “salvage” therapy in critically
ill patients (1, 7, 9, 11). CMS is converted in vivo to colistin,
and these two entities have substantially different pharmaco-
kinetics, antibacterial activities, and toxicities (7), and there-
fore it is important to understand the dispositions of both.
Patients who are currently being treated with CMS include
many in the intensive care setting with multiple organ dysfunc-
tions and receiving renal replacement therapy (10). Goodwin
et al. reported the effects of renal impairment, peritoneal di-
alysis, and hemodialysis on the concentrations of CMS in se-
rum (3); unfortunately, the microbiological assays employed
failed to measure colistin and CMS separately. Moreover, the
efficiency of the hemodialyzer used in the 1968 report of Good-
win et al. may be different from that of current hemofilter
units. To date, there is a dearth of information in critically ill
patients on the clinical pharmacokinetics of CMS and the
generated colistin to guide the selection of dosage regimens of
CMS.
We describe here the case of a 53-year-old woman (110 kg;
ideal body weight, 61 kg) who presented with bowel perfora-
tions leading to multiple organ failure requiring continuous
venovenous hemodiafiltration (CVVHDF). CVVHDF (2) was
performed with 1 liter/h of dialysate and 2 liters/h of postdilu-
tion replacement fluid, producing 3 liters/h of dialysis effluent;
blood flow was set at 200 ml/min through an extracorporeal
circuit containing a Hospal AN69HF hemofilter. Systemic to-
bramycin had been ceased on day 20 of hospital admission due
to decreased renal function and nebulized tobramycin (80 mg
every 8 h) was commenced. Due to an infection caused by a
new multidrug-resistant Pseudomonas aeruginosa strain iso-
lated in endotracheal aspirate, which was susceptible only to
colistin and tobramycin, intravenous CMS at a dosage of 150
mg (equivalent to 2.46 mg per kg of ideal body weight) every 24
h was commenced on day 24 of admission and changed to 150
mg/48 h on day 38 (12, 14). Each dose was administered as a
30-min infusion. Meropenem and nebulized tobramycin were
coadministered. After CMS administration on day 44, blood
and effluent dialysate were collected up to 48 h postdose for
high-performance liquid chromatography quantification of
CMS (5) and colistin (4) in plasma and dialysate (accuracy
within 14.1% and coefficients of variation less than 6.66%), to
permit pharmacokinetic analysis. MICs of CMS and colistin
were determined by broth microdilution (13).
The concentrations of CMS and colistin in plasma and dia-
lysate are shown in Fig. 1. The maximum concentration of
colistin in plasma occurred 30 min after completion of the
CMS infusion, consistent with relatively rapid conversion to
colistin (6). The terminal half-lives of CMS and colistin in
plasma were 6.83 h and 7.52 h, respectively. The total clearance
of CMS was 48.7 ml/min and its volume of distribution was 10.9
liters. From 0 to 8 h after dosing, 20.3% of the dose was
recovered in the dialysate as CMS and 6.88% as colistin. CV-
VHDF clearances of CMS (11.2 ml/min) and colistin (11.9
ml/min) were similar.
The MICs of CMS and colistin against the P. aeruginosa
isolate from the patient were 4.0 mg/liter and 1.0 mg/liter,
respectively. The maximum concentrations of CMS and colis-
tin in plasma were 23.3 mg/liter and 1.84 mg/liter, respectively
(Fig. 1). Even without the consideration of plasma protein
binding, the maximum concentration for CMS in plasma was
less than 16MIC and that for colistin was less than 2MIC;
rapid killing and significant postantibiotic effect in vitro against
P. aeruginosa has been shown to occur above these MIC
thresholds (8). In addition and importantly, the plasma con-
FIG. 1. Concentrations of CMS and colistin in plasma and dialysate after CMS administration (150 mg/48 h) on day 44. Concentrations in
plasma and dialysate were not quantifiable beyond 24 h and 9 to 11 h, respectively.
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centrations of CMS and colistin fell below their respective
MICs approximately 4 h following administration of CMS.
Thus, plasma concentrations were below the respective MICs
for a very large proportion of the 48-h dosage interval.
The product information (12, 14) for CMS injection is un-
helpful in relation to the selection of appropriate dosage reg-
imens in critically ill patients receiving renal replacement ther-
apy. For patients with renal impairment, the product
information suggests to essentially maintain the size of each
dose while extending the dosage interval (12, 14), as occurred
in the patient in the present study. The product information
available in Australia is silent on whether CMS is cleared by
dialysis (14), while the product information available in the
United States claims that it is not known if CMS is cleared by
dialysis (12). In the present case, we have demonstrated that
both CMS and colistin are indeed cleared by CVVHDF. Un-
fortunately, on day 50 of admission, the patient arrested from
hypovolemic and septic shock and died. Clearly, the CMS
dosage regimen (150 mg [2.46 mg per kg of ideal body weight]
every 48 h) was not appropriate for this patient. Based on the
data obtained from the present case, it is likely that dosage
adjustment for CMS in CVVHDF patients should be more
modest (e.g., 2 to 3 mg/kg every 12 h) than that employed for
this patient; more definitive dosage recommendations require
studies of other patients.
(This study will be presented at the 45th Interscience Con-
ference on Antimicrobial Agents and Chemotherapy, Wash-
ington, D.C., 16 to 19 December 2005.)
We acknowledge the Australian National Health and Medical Re-
search Council.
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